{
    "symbol": "IRIX",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 22:06:05",
    "content": " Lastly, our focus on cash management and well funded operating runway have delivered stability to invest in growth vehicles of product launches, targeted clinical data and publications, physician training and recently inventory management to de-risk potential supply chain issues such as carrying extra inventory and prepaying suppliers to secure commitments later in the year. Delivering further data supporting the use of TLT by comprehensive ophthalmologists for pre incisional treatment of more moderate stage glaucoma patients expanding the size and geographic reach of our U.S. sales team, and internationally, we plan to expand into new markets, including anticipated regulatory clearance in China later this year, as well as additional bundled tender programs in collaboration with Topcon. We continue to expect total revenue for the fiscal year 2022 to be $57 million to $59 million, G6 probe unit sales are expected to range from $67,000 to $70,000 and Cyclo G6 Glaucoma Laser Systems installed base is expected to expand by 225 to 250 units."
}